Revelation Biosciences, Inc. SEC filings REVB
Revelation Biosciences, Inc. has 389 filings in SEC EDGAR's recent list, going back to May 14, 2020. Its latest annual report, Form ARS, was filed on May 11, 2026 for the period ended May 11, 2026. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-A12B | Filing | Jul 13, 2026 | — |
| EFFECT | Filing | Feb 11, 2026 | — |
| CORRESP | Letter to the SEC | Feb 9, 2026 | — |
| UPLOAD | Letter from the SEC | Feb 6, 2026 | — |
| EFFECT | Filing | Sep 30, 2025 | — |
| CORRESP | Letter to the SEC | Sep 29, 2025 | — |
| CORRESP | Letter to the SEC | Sep 29, 2025 | — |
| UPLOAD | Letter from the SEC | Sep 24, 2025 | — |
| EFFECT | Filing | May 28, 2025 | — |
| CORRESP | Letter to the SEC | May 23, 2025 | — |
| CORRESP | Letter to the SEC | May 22, 2025 | — |
| CORRESP | Letter to the SEC | May 22, 2025 | — |
| UPLOAD | Letter from the SEC | May 21, 2025 | — |
| CORRESP | Letter to the SEC | May 20, 2025 | — |
| UPLOAD | Letter from the SEC | Apr 9, 2025 | — |
| DRS | Filing | Apr 4, 2025 | — |
| EFFECT | Filing | Dec 20, 2024 | — |
| CORRESP | Letter to the SEC | Dec 20, 2024 | — |
| CORRESP | Letter to the SEC | Dec 19, 2024 | — |
| UPLOAD | Letter from the SEC | Dec 18, 2024 | — |
| UPLOAD | Letter from the SEC | Sep 25, 2024 | — |
| CORRESP | Letter to the SEC | Sep 23, 2024 | — |
| UPLOAD | Letter from the SEC | Sep 13, 2024 | — |
| EFFECT | Filing | Sep 12, 2024 | — |
| CORRESP | Letter to the SEC | Sep 10, 2024 | — |
| UPLOAD | Letter from the SEC | Sep 9, 2024 | — |
| EFFECT | Filing | Jul 26, 2024 | — |
| CORRESP | Letter to the SEC | Jul 23, 2024 | — |
| UPLOAD | Letter from the SEC | Jul 23, 2024 | — |
| EFFECT | Filing | Jan 31, 2024 | — |
| CORRESP | Letter to the SEC | Jan 30, 2024 | — |
| CORRESP | Letter to the SEC | Jan 29, 2024 | — |
| UPLOAD | Letter from the SEC | Jan 2, 2024 | — |
| NT 10-Q | Filing | May 15, 2023 | Mar 31, 2023 |
| EFFECT | Filing | Feb 9, 2023 | — |
| CORRESP | Letter to the SEC | Feb 6, 2023 | — |
| CORRESP | Letter to the SEC | Feb 1, 2023 | — |
| 25-NSE | Delisting notice | Jan 13, 2023 | — |
| EFFECT | Filing | Nov 18, 2022 | — |
| CORRESP | Letter to the SEC | Nov 17, 2022 | — |
| CORRESP | Letter to the SEC | Nov 16, 2022 | — |
| UPLOAD | Letter from the SEC | Nov 14, 2022 | — |
| EFFECT | Filing | Jul 25, 2022 | — |
| CORRESP | Letter to the SEC | Jul 25, 2022 | — |
| UPLOAD | Letter from the SEC | Jul 18, 2022 | — |
| EFFECT | Filing | Jun 10, 2022 | — |
| CORRESP | Letter to the SEC | Jun 7, 2022 | — |
| UPLOAD | Letter from the SEC | Jun 6, 2022 | — |
| NT 10-K | Notification of late filing | Mar 31, 2022 | Dec 31, 2021 |
| EFFECT | Filing | Feb 7, 2022 | — |
| CORRESP | Letter to the SEC | Feb 3, 2022 | — |
| CORRESP | Letter to the SEC | Feb 3, 2022 | — |
| UPLOAD | Letter from the SEC | Feb 2, 2022 | — |
| CORRESP | Letter to the SEC | Jan 28, 2022 | — |
| EFFECT | Filing | Dec 14, 2021 | — |
| CORRESP | Letter to the SEC | Dec 14, 2021 | — |
| CORRESP | Letter to the SEC | Dec 6, 2021 | — |
| UPLOAD | Letter from the SEC | Nov 26, 2021 | — |
| CORRESP | Letter to the SEC | Nov 4, 2021 | — |
| 425 | Form 425 | Nov 1, 2021 | — |
| UPLOAD | Letter from the SEC | Oct 25, 2021 | — |
| 425 | Filing | Oct 25, 2021 | — |
| 425 | Form 425 | Oct 4, 2021 | — |
| 425 | Form 425 | Sep 28, 2021 | — |
| DEFR14A | Definitive proxy statement | Sep 24, 2021 | — |
| 425 | Current report | Sep 2, 2021 | — |
| NT 10-Q | Notification of late filing | Aug 17, 2021 | Jun 30, 2021 |
| NT 10-Q | Notification of late filing | May 18, 2021 | Mar 31, 2021 |
| CERT | Filing | Oct 9, 2020 | — |
| EFFECT | Filing | Oct 7, 2020 | — |
| 8-A12B | For registration of certain classes | Oct 7, 2020 | — |
| DRS | Filing | May 14, 2020 | — |
Showing 72 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- REVB (Nasdaq), REVBW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1810560
- Former names
- Petra Acquisition Inc. (until Jan 11, 2022)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.